[Indications and utility of allergen provocation testing]

Area of Science:

• Allergy and Immunology
• Respiratory Medicine
• Clinical Diagnostics

Background:

• Bronchial provocation tests (BPTs) are used for asthma diagnosis and immunotherapy efficacy assessment.
• Despite advances in asthma understanding, BPTs face methodological challenges.
• Limitations include evaluating inflammatory markers and timing, ideal respiratory function parameters, and mimicking natural allergen exposure.

Purpose of the Study:

• To critically evaluate the methodological limitations of allergen-specific bronchial provocation tests in asthma.
• To discuss the implications of these limitations on asthma diagnosis and immunotherapy.
• To highlight the need for improved standardization and interpretation of BPTs.

Main Methods:

• Review of current methodologies and limitations of allergen-specific bronchial provocation tests.
• Analysis of inflammatory markers, respiratory function parameters (e.g., FEV1), and allergen dosing in BPTs.
• Discussion on the impact of allergen standardization and recombinant allergens.

Main Results:

• Current BPTs have difficulties in selecting appropriate inflammatory markers and timing.
• Standard respiratory function parameters (FEV1) may not fully reflect bronchospastic and inflammatory responses.
• Allergen doses in protocols often do not mimic natural exposure, and allergen standardization is lacking.

Conclusions:

• Relying solely on positive BPTs for asthma diagnosis or negative results for immunotherapy efficacy is questionable.
• Bronchial reactivity is influenced by uncontrollable variables like prior allergen exposure.
• Improved standardization, potentially with recombinant allergens, and a nuanced interpretation of BPTs are necessary.